CN117159666A - Medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness mass and preparation method thereof - Google Patents
Medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness mass and preparation method thereof Download PDFInfo
- Publication number
- CN117159666A CN117159666A CN202311211969.9A CN202311211969A CN117159666A CN 117159666 A CN117159666 A CN 117159666A CN 202311211969 A CN202311211969 A CN 202311211969A CN 117159666 A CN117159666 A CN 117159666A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- phlegm
- overweight
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 40
- 208000026435 phlegm Diseases 0.000 title claims abstract description 40
- 235000012054 meals Nutrition 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000008589 Obesity Diseases 0.000 title claims description 49
- 235000020824 obesity Nutrition 0.000 title claims description 49
- 206010033307 Overweight Diseases 0.000 title claims description 40
- 239000000843 powder Substances 0.000 claims abstract description 109
- 244000197580 Poria cocos Species 0.000 claims abstract description 20
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 15
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 15
- 240000002943 Elettaria cardamomum Species 0.000 claims abstract description 15
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 claims abstract description 15
- 241000046198 Triteleia hyacinthina Species 0.000 claims abstract description 15
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 15
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 15
- 235000020224 almond Nutrition 0.000 claims abstract description 15
- 235000005300 cardamomo Nutrition 0.000 claims abstract description 15
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 13
- 229920002752 Konjac Polymers 0.000 claims abstract description 13
- 235000010485 konjac Nutrition 0.000 claims abstract description 13
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 32
- 235000013305 food Nutrition 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000005911 diet Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 11
- 229930186217 Glycolipid Natural products 0.000 abstract description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 10
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 9
- 230000004060 metabolic process Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 230000008021 deposition Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 51
- 244000046052 Phaseolus vulgaris Species 0.000 description 18
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 18
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- 229960001243 orlistat Drugs 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 102000007156 Resistin Human genes 0.000 description 5
- 108010047909 Resistin Proteins 0.000 description 5
- 210000000579 abdominal fat Anatomy 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 208000001797 obstructive sleep apnea Diseases 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108700004049 glycosylated serum Proteins 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 description 1
- 108050003337 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101150006655 INS gene Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 101100289192 Pseudomonas fragi lips gene Proteins 0.000 description 1
- 102100024735 Resistin Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 101150091950 retn gene Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000008782 xin-kang Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a medicinal and edible meal replacement composition for improving phlegm-damp overweight/obese people and a preparation method thereof, wherein the composition comprises the following components in parts by weight: 7-11 parts of almond powder, 13-17 parts of coix seed powder, 1-5 parts of cardamon seed powder, 13-17 parts of red bean powder, 7-11 parts of poria cocos powder, 4-8 parts of white hyacinth bean powder, 20-24 parts of konjak refined powder and 19-22 parts of oligomeric maltose. The composition provided by the application can regulate the glycolipid metabolism of a simple obese model rat, improve fat deposition and insulin resistance in vivo, inhibit the inflammation level of the obese model rat and improve the biological antioxidant capacity of organisms.
Description
Technical Field
The application relates to the technical field of traditional Chinese medicines, in particular to a medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness, a traditional Chinese medicine preparation and a preparation method thereof.
Background
With the improvement of the physical and living standard of people, the dietary structure and the living style are radically changed, the incidence of overweight and obesity is rapidly increased, and the obesity is the most popular nutritional disorder in the world. Overweight/obesity is an important risk factor for a variety of chronic diseases, especially cardiovascular and cerebrovascular diseases. Studies have shown that obesity is a major high risk factor for developing hypertension, with higher body mass index leading to higher incidence of hypertension. At the same time, overweight, obesity increase the risk of stroke, and this risk may appear to increase stepwise with increasing body weight. Among them, early-onset atherosclerosis is a major cause of ischemic stroke. In addition, obesity is also a major risk factor for acute myocardial infarction. Obesity can also aggravate the conditions of hypertension, diabetes and lipid abnormality, cause difficult prevention and treatment of coronary heart disease, increase heart load, damage heart function, easily cause nocturnal sleep apnea, and induce sudden death.
Obesity is also an important risk factor for the development of type 2 diabetes, and central obesity is an independent risk factor for type 2 diabetes. The central distribution of obesity and body fat can lead to reduced insulin receptors in peripheral tissue cells, reduced avidity, and often accompanied by receptor defects, reduced insulin sensitivity, increased islet cell burden, and ultimately diabetes. Studies have shown that overweight and obesity are also the main etiologies and key links in the development and progression of metabolic syndrome. The effects of overweight and obesity on the human body are manifold and are also closely related to many other systemic diseases.
Obesity is one of the risk factors for the onset of obstructive sleep apnea-hypopnea syndrome (OSAHS), and the severity of OSAHS is positively correlated with obesity. Obesity is also an important risk factor for osteoarthritis, and has a very important influence on both weight bearing and non-weight bearing arthritis, leading to pain, reduced quality of life, etc. in patients. In addition, obesity affects the endocrine system, can lead to menstrual disorder, ovulation failure, and even fertility in women. In addition, overweight and obesity lead to reduced exercise capacity and more psychological problems. Therefore, overweight and obesity are one of the important problems to be solved urgently in the medical field, and have important significance in improving the glycolipid metabolic disorder caused by obesity and preventing and treating cardiovascular and cerebrovascular diseases.
The understanding of overweight/obesity in traditional Chinese medicine is profound, and is called as "meat man" and "fat man" in ancient times, and the occurrence causes are mostly related to three factors of dampness, phlegm and deficiency. Several chapters in Huangdi's Nei Jing all talk about overweight/obesity problems, such as "Su-Tong-Di-Xie-excess theory" are called: "fat noble people will get paste beam disease. "Lingqiu, reverse-forward fat lean Teng" also cloud: "fertile man also … is a man who is also greedy to take and connect. "overweight/obese characteristics are also described in detail: obesity in body shape; fat-rich and thick skin; blood is changed by more common people, and is considered to be sticky and slow to run. The postnatal Chen Xiuyuan: the general nature of essence is not bitter, but rather excessive phlegm. "Wang Angyan: the people who are fat can get excessive phlegm and stop menstruation, and qi is not transported. "the crowd has excessive food intake, is sweet and sweet in taste, and is paste Liang Houwei, and fat accumulation is caused by accumulation of grain essence into paste fat in human body. Sweet and thick taste can damage yang qi of spleen and stomach, which results in weakening of spleen and stomach transportation and transformation function, and damp is generated and left in orifices and skin. The ingested food and energy cannot be changed into microscopic substances required by the human body to be absorbed by the human body, but instead become pathological products, namely phlegm, turbidity and fat, which accumulate in the body, accumulate and jam, and finally cause fat accumulation.
However, meal replacement compositions based on traditional Chinese medicinal components for improving overweight/obesity of the phlegm-dampness nature have not been seen in the related art.
The present application has been made in view of this.
Disclosure of Invention
The application aims to overcome the defects of the prior art, and provides a medicinal and edible meal replacement composition for improving overweight/obesity of phlegm-damp type, a traditional Chinese medicine preparation and a preparation method thereof, which can regulate the glycolipid metabolism of a simple overweight/obese rat, improve fat deposition and insulin resistance in vivo, inhibit the inflammation level of the obese rat and improve the biological antioxidant capacity of organisms.
In order to achieve the technical purpose, the application adopts the following technical scheme:
according to one aspect of the application, a medicine and food homologous meal replacement composition for improving phlegm-damp type obese people is provided, and is characterized by comprising the following components in parts by weight: 7-11 parts of almond powder, 13-17 parts of coix seed powder, 1-5 parts of cardamon seed powder, 13-17 parts of red bean powder, 7-11 parts of poria cocos powder, 4-8 parts of white hyacinth bean powder, 20-24 parts of konjak refined powder and 19-22 parts of oligomeric maltose.
Optionally, the composition comprises the following components in parts by weight:
7 parts of almond powder, 17 parts of coix seed powder, 1 part of cardamon seed powder, 17 parts of red bean powder, 7 parts of poria cocos powder, 8 parts of white hyacinth bean powder, 20 parts of konjak refined powder and 22 parts of oligomeric maltose.
Optionally, the composition comprises the following components in parts by weight:
11 parts of almond powder, 13 parts of coix seed powder, 5 parts of cardamon seed powder, 13 parts of red bean powder, 11 parts of poria cocos powder, 4 parts of white hyacinth bean powder, 24 parts of konjak refined powder and 19 parts of oligomeric maltose.
Optionally, the composition comprises the following components in parts by weight: 9 parts of almond powder, 15 parts of coix seed powder, 3 parts of cardamon seed powder, 15 parts of red bean powder, 9 parts of poria cocos powder, 6 parts of white hyacinth bean powder, 22 parts of konjak refined powder and 21 parts of oligomeric maltose.
The application also provides a traditional Chinese medicine preparation, and the raw material medicine of the traditional Chinese medicine preparation is the medicine and food homologous meal replacement composition for improving phlegm-dampness overweight/obese people.
The application also provides a preparation method of the medicine and food homologous meal replacement composition for improving overweight/obesity with phlegm-dampness, which comprises the following steps:
the components in the medicine and food homologous meal replacement composition for improving overweight/obesity with phlegm-dampness are prepared according to the above steps;
the components are sent into a dryer for drying, and the moisture content of each food/decoction piece after drying is controlled below 8 percent;
and (3) respectively conveying each dried component into a micronizing machine for grinding and crushing, respectively conveying the components into a superfine pulverizer to prepare superfine powder, controlling the granularity of the superfine powder to be 50-300 meshes, and preparing the superfine powder into the edible superfine powder composition according to the weight parts of the components in the composition.
Optionally, the preparation method further comprises:
the edible superfine micropowder composition is prepared into powder (paste), granule, capsule, soft capsule, granule, dripping pill or soft extract.
Optionally, the granularity of the superfine powder is controlled to be 80-200 meshes.
Optionally:
the water content of each food/decoction piece after drying is controlled below 8%.
The medicinal and edible meal replacement composition for improving the overweight/obesity of the phlegm-damp type provided by the application adopts a medicinal and edible three-kernel bean poria cocos formula, and researches the influence on the metabolism of the relevant organs, peripheral fat and glycolipid of the phlegm-damp type simple overweight/obesity rat. By detecting the indexes of glycolipid metabolism, insulin resistance, fat factors and lipid peroxidation resistance. Pathological morphology HE staining observed microscopic changes in rat liver, kidney and surrounding adipose tissue. The results show that the composition provided by the application, namely the medicinal and edible homologous three-kernel bean poria prescription, can regulate the glycolipid metabolism of a simple overweight/obese rat, improve fat deposition and insulin resistance in vivo, inhibit the inflammation level of the overweight/obese rat and improve the biological antioxidant capacity of the organism. The composition can be made into Chinese medicinal preparation with weight reducing effect, and can be directly administered orally or made into other dosage forms such as powder (paste), granule, capsule, soft capsule, granule, dripping pill, and soft extract.
Drawings
Fig. 1 is a schematic diagram of a pathological observation (he×100) of three kernel bean jelly on rat kidney and peripheral fat (a, normal group; B, model group; C, orlistat group; D, three kernel low dose group; E, three kernel high dose group; the upper half is kidney tissue, the lower half is fat tissue around kidney) of a pharmaceutical and edible meal replacement composition for improving overweight/obesity with phlegm dampness;
fig. 2 is a schematic diagram showing pathological observation (he×100) of three-kernel bean jelly on rat liver and abdomen fat (a, normal group, B, model group, C, orlistat group, D, three-kernel low dose group, E, three-kernel high dose group, upper half of liver tissue and lower half of abdominal fat tissue) of a pharmaceutical and edible composition for improving phlegm-dampness overweight/obesity according to an embodiment of the present application.
Detailed Description
In order that those skilled in the art will better understand the present application, a technical solution in the embodiments of the present application will be clearly and completely described below with reference to the accompanying drawings in which it is apparent that the described embodiments are only some embodiments of the present application, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present application without making any inventive effort, shall fall within the scope of the present application.
From the medical point of view, the inventor considers that phlegm-dampness is a key pathogenesis of overweight/obesity, and is related to spleen, lung, kidney and triple energizer due to improper diet, spleen deficiency dampness accumulation, emotional disorder, qi stagnation and fluid withdrawal and the like. Overweight/obesity is treated by diffusing the lung, strengthening the spleen, tonifying the kidney, resolving dampness, and regulating the passage of water, with attention paid to the spleen, lung and kidney.
Example 1
The medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness can be clinically called as a three-kernel bean jelly formula, and can be used as an intervention means for overweight/obesity with phlegm-dampness. In the embodiment, the three-kernel bean poria cocos formula comprises the following components: 9g of almond powder, 15g of coix seed powder, 3g of cardamon seed powder, 15g of red bean powder, 9g of poria cocos powder, 6g of white hyacinth bean powder, 22g of konjak refined powder and 21g of isomaltooligosaccharide.
After each Chinese herbal medicine decoction piece is selected by a material selecting machine, the Chinese herbal medicine decoction piece is conveyed into a dryer for drying, and the moisture content of each Chinese herbal medicine decoction piece after drying is controlled below 8%. And respectively inputting each dried traditional Chinese medicine decoction piece into a micronizer for grinding and crushing, respectively inputting into an ultrafine grinder for preparing ultrafine powder, controlling the granularity to be 80-200 meshes, preparing the ultrafine powder traditional Chinese medicine into edible traditional Chinese medicine ultrafine powder according to a proportion, putting 1g crude drug/g traditional Chinese medicine ultrafine powder decoction pieces into an inner package for infrared disinfection and sterilization, and quantitatively packaging. Convenient to store, can be eaten at any time, and can be taken with boiled water one bag at a time.
The medicinal and edible meal replacement composition can also be used as a traditional Chinese medicine composition, namely, a raw material medicine of a traditional Chinese medicine preparation, and is prepared into powder (paste), granules, capsules, soft capsules, medicinal granules, dripping pills, soft extract and the like by being matched with corresponding excipients and the like.
Example 2
Compared with the embodiment 1, the embodiment is different in the proportion of each component, specifically: 11g of almond powder, 13g of coix seed powder, 5g of cardamon seed powder, 13g of red bean powder, 11g of poria cocos powder, 4g of white hyacinth bean powder, 24g of konjak refined powder and 19g of oligomeric maltose.
The rest of the preparation method is the same as in example 1.
Example 3
Compared with the embodiment 1, the embodiment is different in the proportion of each component, specifically: 7g of almond powder, 17g of coix seed powder, 1g of cardamon seed powder, 17g of red bean powder, 7g of poria cocos powder, 8g of white hyacinth bean powder, 20g of konjak refined powder and 22g of oligomeric maltose.
The rest of the preparation method is the same as in example 1.
The functional indications of the composition provided by the embodiment, namely the three-kernel bean poria cocos prescription, comprise:
the three-kernel bean poria prescription takes almonds, cardamon seeds and coix seeds as monarch drugs, and by dispersing upper, middle and lower energizers and simultaneously excreting, three-jiao damp turbidity is eliminated, the almonds are Wen Wei bitter, xuan Li upper-jiao lung qi is humidified when qi flows, and the three-kernel bean poria prescription has the efficacy of warming and moistening large intestine channels and can promote the excretion of damp evil from lower-jiao channels; the cardamon seed has Wen Weixin effects of resolving dampness and promoting qi circulation, promoting qi circulation and relieving middle energizer, and smoothing spleen qi of middle energizer, and has good curative effect on incoordination between spleen and stomach, and can be used for expelling phlegm dampness from spleen of middle energizer; coix seed, semen Coicis, sweet and cold in nature, excretes dampness and promotes diuresis to invigorate the spleen, and promotes entry of damp-heat into the lower jiao to relieve constipation. The three medicines of red bean, poria and white hyacinth bean are sweet, flat and light in permeability, and the functions of assisting the monarch drug in strengthening spleen, resolving dampness and promoting diuresis are ministerial drugs. The red bean has sweet and sour taste, is neutral in nature, and has the effects of inducing diuresis to alleviate edema, removing toxicity and expelling pus; poria is sweet and light in taste and mild in nature, and has the effects of promoting diuresis, removing dampness and strengthening spleen; white hyacinth bean is sweet in taste and slightly warm in nature, and can strengthen spleen to dispel dampness and harmonize middle energizer.
The following describes the effects of the pharmaceutical and edible meal replacement composition for improving overweight/obesity with phlegm-dampness according to the embodiment of the application through related experiments. For convenience of description or illustration, the following test examples include "three-kernel", "three-kernel group", "three-kernel high dose group", "three-kernel low dose group", and the like, where "three-kernel" refers to the pharmaceutical and food homologous composition for improving phlegm-dampness obesity provided by the embodiments of the present application.
1. Materials and methods
1.1 laboratory animals
Sprague-Dawley (SD) rats, male and female halves, SPF grade, body mass (200+ -20) g, offered by Peking Vitre Liwa laboratory animal technologies Co., ltd., animal eligibility: SCXK (Beijing) 2019-0010. Barrier-grade animal room feeding, timing feeding of complete nutritional feed, rat maintenance feed provided by the company australia of beijing, feed limited, feed eligibility: SCXK (Beijing) 2019-0010. The experiment is carried out after the room temperature (22-25) DEG C, the humidity of 50-70%, the illumination for 12 hours and the darkness for 12 hours are adapted to the 1 week of feeding.
Rat high-fat high-sugar feed (15% fat/lard, 1% cholesterol, 0.2% sodium cholate, 0.2% propylthiouracil, 83.6% basal feed), produced by the company australian synergetic feed limited in beijing, feed qualification certificate: SCXK (Beijing) 2019-0010.
1.2 Experimental drugs
The composition of example 1, the three kernel bean bag formula, was used as follows: 9g of almond powder, 15g of coix seed powder, 3g of cardamon seed powder, 15g of red bean powder, 9g of poria cocos powder, 6g of white hyacinth bean powder, 22g of konjak fine powder and 21g of isomaltooligosaccharide, wherein the Chinese herbal pieces are purchased from Xinkang International medical biotechnology (Guangzhou) Co., ltd, 1g of crude drugs/g and are processed by Shanxi Zhengdong pharmaceutical company, batch number: 20210201; orlistat capsule (60 mg/pellet), lot number: h20143118, manufactured by the new era of pharmaceutical industry, inc.
1.3 Experimental reagents and instruments
Total Cholesterol (TCHO), triglyceride (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), glucose (GLD), and Glycosylated Serum Protein (GSP) kits are all manufactured by German Roche diagnostics, inc., with lot numbers 653037, 653219, 652308, 651092, 652128, 667283, 656438, 656036, 650614, respectively; interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) ELISA kits were produced by Beijing Xinbo biosciences, inc., and the lot numbers were 20210512 and 20210430, respectively; the C-Peptide (C-Peptide), insulin (INS), insulin antibody, pancreatic lipase activity (LPS), adiponectin (ADP), and Resistin (Resistin) kits are all manufactured by Beijing-type English Biotechnology research, with lot numbers 20210602, 20210605, 20210601, 20210603, 20210604, 20210606; leptin (LP) kit was manufactured by shandongbo industry limited, lot number 20210602; the Free Fatty Acid (FFA), superoxide dismutase (SOD), malondialdehyde (MDA), glutathione-peroxidase (GSH-Px) and reduced Glutathione (GSH) kits are all produced by Nanjing institute of biological engineering, and the batch numbers are 20210610, 20210602, 20210601, 20210607 and 20210612 respectively.
ROCHE/E601 type, fully automatic electrochemiluminescence immunoassay, manufactured by ROCHE (swiss) instruments inc; model A6, semiautomatic biochemical analyzer manufactured by beijing pine upper technology limited company; DR-200BS type, semi-automatic microplate reader was manufactured by tin-free Hua Weide Langmuir instruments Co.
1.4 Experimental methods
1.4.1 preparation of a model of a simple overweight/obese rat with phlegm-dampness
A high-fat diet-induced phlegm-dampness type simple overweight/obese rat model was established. SD rats were randomly divided into 10 rats in the control group, fed with normal diet, 60 animals with simple obesity, and fed with high fat diet. After 4 weeks, the degree of obesity of the rats was evaluated according to the stratified group of the body weights of the rats, and those having a body weight exceeding 20% of the normal body weight were selected as a model of a phlegm-damp type simple obesity rat.
1.4.2 administration group
The obese rats 40 were divided into 4 groups according to the random number table, an obese model group (model group), a positive control drug group (western drug group, orlistat 16.20mg/kg body mass), a three-kernel bean poria cocos low dose group (three-kernel low group, 2.21g crude drug/kg body mass), and a three-kernel bean poria cocos high dose group (three-kernel high group, 4.42g crude drug/kg body mass), each group of 10 animals. The administration dosage is converted according to the daily clinical dosage of adults and the body surface coefficients of human and animals. The normal group and the model group are irrigated with distilled water with equal volume, and each administration group is allocated with the same volume of medicine for the gastric lavage administration, 1 time a day. During the experiment, the body mass of the rats and the consumption of the feed were weighed once a week, and the amount of the feed was adjusted according to the body weight. During the period of stomach irrigation, rats are free to drink water, normal rats are fed with normal feed, and the rest rats are fed with high-fat feed. After 4 weeks, rats were anesthetized (2% sodium pentobarbital aqueous solution 0.2ml/100g mass), abdominal aorta was sampled, serum was isolated, sub-packaged and stored in-80 ℃ refrigerator, and relevant serum biomarker index was detected. The treatment of the animal by the experiment meets the animal ethical requirements specified by the national institutes of science and technology (the regulations on the management of experimental animals) and the ethical examination guidelines on welfare of experimental animals in Beijing, and is approved by the ethical committee of the West Yuan hospital of Chinese medical college of China (No. 2021XLC 012-2).
1.4.3 detection of glycolipid metabolism index
The detection method of TCHO, HDL-C and LDL-C adopts an enzyme colorimetric method; the TG detection method adopts a colorimetric method; GLD detection method adopts hexokinase method.
1.4.4 serum insulin class index determination
IL-6, TNF-alpha, C-peptide, ins, insulin antibodies, lips, ADPN, RSTN detection methods using enzyme-linked immunosorbent assay (ELISA); LP, FFA, SOD, MDA, GSH-Px and GSH detection method adopts a colorimetric method.
1.4.5 rat tissue treatment methods
After blood collection, the rats were rapidly removed for kidney/kidney fat, ovary/ovary fat, liver and abdomen fat, epididymis/epididymis fat, and fixed in 10% neutral formaldehyde solution according to random number. Paraffin sections 4 μm, dewaxing, HE staining, dehydration sealing, light microscopy analysis.
1.5 statistical treatments
SPSS20.0 was selected for statistical analysis, and the data were measured as mean.+ -. Standard deviationAnd (3) representing. Data were normalized and checked for variance, one-factor analysis of variance was used for comparison between groups, LSD was used for variance, dunnett T3 for variance was used for variance, P<0.05 is statistically significant.
2. Results
2.1 the composition provided by the embodiment of the application, namely, the influence of the three-kernel bean bag prescription on the body quality of rats
The quality of the administered precursor of each group of rats is obviously increased compared with that of the normal group, the quality of the administered precursor of each group of rats is statistically different (P is less than 0.01), the quality of the administered precursor of each group of rats is reduced by 4 weeks, and the quality of the administered precursor of each group of rats is not statistically different from that of the administered precursor of each group of rats in the model group, namely the quality of the three-kernel high-dose group and the quality of the three-kernel low-dose group are reduced by the dose group of the application. Female group, compared with model group, orlistat group, three-kernel high-dose group and low-dose group have significantly reduced quality, have statistical difference (P < 0.01), and have no significant difference (P > 0.05)
TABLE 1 comparison of rat body Mass by SanrenDou Ling formula
Note that: in comparison with the normal group, * P<0.05, ** P<0.01; in comparison with the set of models, # P<0.05, ## P<0.01
2.2 the composition provided by the embodiment of the application, namely, the three-kernel bean poria cocos formula is used for observing the pathological morphology of the kidney, liver and peripheral fat of the rat
Under an optical microscope, the glomerular vascular loop of a normal rat kidney is thin and clear, mesangial cells, epithelial cells and endothelial cells are normal, basement membrane is not widened, renal tubules are normal, and the volume of adipose tissue cells around the kidney is large and the number of adipose tissue cells is small. The model group had kidney mesangial cells and mesangial matrix hyperplasia, basement membrane thickening, glomerular bowman's capsule broadening, uniform glomerular volume enlargement, individual with segmental glomerulosclerosis and mild tubular atrophy, and peripheral adipocytes became smaller and increased in number. After treatment of each treatment group, the proliferation phenomenon of endothelial cells and mesangial cells of the kidney is improved to a certain extent, the enlarged forms of basal lamina and glomerular volume are inhibited to a certain extent, and peripheral fat cells of the kidney are reduced to a certain extent and increased in number, wherein the effects of the orlistat group and the three-kernel high-dose group are obvious.
Under an optical microscope, liver lobular tissues of a liver of a normal rat are clear, liver cells are uniform in size, cell nuclei are clear, boundaries among cells are clear, fat drops are few, and abdominal fat tissue cells are uniform in volume and moderate in quantity. The liver cells of the model group are steatosis, the cytoplasm is provided with fat drops (vacuoles) with different sizes, the volume of the liver cells is increased, the liver cells are slightly swelled, partial inflammatory cells infiltrate, the liver blood vessel intima is thickened, and the fat cells of the abdomen are densely and increased. After treatment of each treatment group, the hepatic cell steatosis phenomenon is relieved to a certain extent, the volume increase of hepatic cells is improved, and the accumulation of abdominal fat cells is relieved to a certain extent, wherein the effects of the orlistat group and the three-kernel high-dose group are obvious. The results are shown in FIG. 1 and FIG. 2.
2.3 effects of the composition provided by the embodiment of the application, namely, the three-kernel bean bag prescription on rat viscera and peripheral fat
Compared with the normal group, the liver weight of the rat in the model group is increased (P is less than 0.05), the kidney weight has no statistical significance (P is more than 0.05), the kidney fat weight is obviously reduced, and the liver weight has statistical difference (P is less than 0.01). Compared with the model group, the weight of the liver and the kidney of the orlistat group, the three-kernel low-dose group and the high-dose group have no statistical difference (P is more than 0.05 and P is more than 0.05), and the kidney fat is obviously reduced (P is less than 0.01 and P is less than 0.05).
The weight of epididymis and epididymal fat of male rats in the model group was significantly increased (P < 0.01, P < 0.05) compared with that in the normal group. There was no statistical difference in epididymal weights (P > 0.05) in the orlistat and three-kernel low and high dose groups compared to the model group, there was a significant decrease in epididymal fat weights (P < 0.01, P < 0.05) in the orlistat and three-kernel high dose groups compared to the model group, and no statistical difference (P > 0.05) in the three-kernel low group.
There was no statistical difference in ovarian weight (P > 0.05) in female rats in the model group compared to the normal group, and the ovarian fat weight was significantly increased (P < 0.01). Compared with the model group, the ovaries of the orlistat group, the trinuclear low-dose group and the high-dose group have no statistical difference (P is more than 0.05), and the weight of the ovarian fat is obviously reduced (P is less than 0.05).
Compared with the normal group, the abdominal fat weight of rats in the phlegm-damp mass model group is obviously increased (P < 0.01). The results of significantly reduced abdominal fat weight (P < 0.01, P < 0.05) in the orlistat, trinuclear low, high dose group compared to the model group are shown in Table 2.
TABLE 2 influence of SanrenDou Ling formula on rat organ tissues and peripheral fat
Note that: and normal groupIn comparison with the comparison result of the comparison, * P<0.05, ** P<0.01; in comparison with the set of models, # P<0.05, ## P<0.01
2.4 effects of the composition provided by the embodiment of the application, namely, the three-kernel bean poria cocos formula on the metabolism index of the rat glycolipid
The rats in the model group had significantly elevated TG, TC and LDL-C levels (P < 0.05, P < 0.01) and no significant HDL-C differences (P > 0.05) compared to the normal group. Compared with the model group, the TC level of the orlistat group and the three-kernel high and low dose group is obviously reduced (P is less than 0.01 and P is less than 0.01), and the three groups have no obvious difference (P is more than 0.05).
The GLU/FRA levels were significantly elevated in the rats of the model group compared to the normal group (P < 0.01 ). Compared with the model group, the GLU level of the orlistat group and the three-kernel high-dose group is obviously reduced (P is less than 0.01 and P is less than 0.01) except the three-kernel low-dose group, and no obvious difference exists between the two groups (P is more than 0.05). Compared with the model group, the FRA of the orlistat group and the three-kernel high and low dose groups is obviously reduced (P is less than 0.01 and P is less than 0.01), and the three groups have no obvious difference (P is more than 0.05). The results are shown in Table 3.
TABLE 3 influence of SanrenDou Poria on the lipid metabolism index of rats
Note that: in comparison with the normal group, * P<0.05, ** P<0.01; in comparison with the set of models, # P<0.05, ## P<0.01
2.5 effects of the composition provided by the examples of the application, namely, the three-seed bean jelly on insulin resistance of rats
The FFA and Resistin levels were significantly elevated in the model rats compared to the normal group (P < 0.01, P < 0.05). Compared with the model group, the FFA and Resistin contents of the orlistat, the trinuclear high and low dose groups are obviously reduced (P is less than 0.01 and P is less than 0.01), the three groups have no obvious difference (P is more than 0.05), the trinuclear high and low dose groups and the orlistat group have obvious difference (P is less than 0.01 and P is less than 0.01) in the aspect of reducing Resistin, and the trinuclear high and low dose groups have no statistical difference (P is more than 0.05). The results are shown in Table 4.
TABLE 4 influence of Sanren Douling on the index of insulin resistance of rats with phlegm-dampness mass model
Note that: in comparison with the normal group, * P<0.05, ** P<0.01; in comparison with the set of models, # P<0.05, ## P<0.01
the above test examples have an effect on metabolism of peripheral fat and glycolipid in rats with simple obesity of phlegm-damp type. By detecting the indexes of glycolipid metabolism, insulin resistance, fat factors and lipid peroxidation resistance. Pathological morphology HE staining observed microscopic changes in rat liver, kidney and surrounding adipose tissue. The results show that the composition provided by the embodiment of the application, namely the medicinal and edible homologous three-kernel bean jelly formula, can regulate the glycolipid metabolism of the simple obese rats, improve the in vivo fat deposition and insulin resistance, inhibit the inflammation level of the obese rats and improve the biological antioxidant capacity of organisms.
The foregoing is merely a preferred embodiment of the present application and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present application, which are intended to be comprehended within the scope of the present application.
Claims (9)
1. A medicinal and edible meal replacement composition for improving phlegm-damp obesity crowd is characterized by comprising the following components in parts by weight: 7-11 parts of almond powder, 13-17 parts of coix seed powder, 1-5 parts of cardamon seed powder, 13-17 parts of red bean powder, 7-11 parts of poria cocos powder, 4-8 parts of white hyacinth bean powder, 20-24 parts of konjak refined powder and 19-22 parts of oligomeric maltose.
2. The pharmaceutical and edible meal replacement composition for improving phlegm-damp obesity according to claim 1, wherein the composition comprises, in parts by weight:
7 parts of almond powder, 17 parts of coix seed powder, 1 part of cardamon seed powder, 17 parts of red bean powder, 7 parts of poria cocos powder, 8 parts of white hyacinth bean powder, 20 parts of konjak refined powder and 22 parts of oligomeric maltose.
3. A pharmaceutical and dietary homologous meal replacement composition for improving a phlegm-damp overweight/obese person as claimed in claim 1, wherein the composition comprises in parts by weight:
11 parts of almond powder, 13 parts of coix seed powder, 5 parts of cardamon seed powder, 13 parts of red bean powder, 11 parts of poria cocos powder, 4 parts of white hyacinth bean powder, 24 parts of konjak refined powder and 19 parts of oligomeric maltose.
4. A pharmaceutical and dietary homologous meal replacement composition for improving a phlegm-damp overweight/obese person as claimed in claim 1, wherein the composition comprises in parts by weight: 9 parts of almond powder, 15 parts of coix seed powder, 3 parts of cardamon seed powder, 15 parts of red bean powder, 9 parts of poria cocos powder, 6 parts of white hyacinth bean powder, 22 parts of konjak refined powder and 21 parts of oligomeric maltose.
5. A traditional Chinese medicine preparation is characterized in that the raw material medicine of the traditional Chinese medicine preparation is the medicine and food homologous meal replacement composition for improving overweight/obese people with phlegm-dampness mass according to any one of claims 1-4.
6. A method for preparing a pharmaceutical and edible meal replacement composition for improving overweight/obesity with phlegm-dampness, which is characterized by comprising the following steps:
a component preparation in a pharmaceutical and dietary homologous meal replacement composition for improving overweight/obesity in the phlegm-damp mass according to any of claims 1 to 4;
the components are sent into a dryer for drying, and the moisture content of each food/decoction piece after drying is controlled below 8 percent;
each of the dried components is respectively sent into a micronizer for grinding and crushing, and is respectively sent into an ultrafine grinder for preparing ultrafine powder, the granularity of the ultrafine powder is controlled to be 50-300 meshes, and the ultrafine powder is prepared into the edible ultrafine powder composition according to the weight proportion of each component in the composition of any one of claims 1-4.
7. A method of preparing a pharmaceutical and dietary homologous meal replacement composition for improving overweight/obesity in the presence of phlegm-dampness according to claim 6, further comprising:
the edible superfine micropowder composition is prepared into powder (paste), granule, capsule, soft capsule, granule, dripping pill or soft extract.
8. The method for preparing a pharmaceutical and edible meal replacement composition for improving overweight/obesity with phlegm-dampness according to claim 6, wherein the granularity of the superfine powder is controlled to be 80-200 meshes.
9. The method for preparing the pharmaceutical and edible meal replacement composition for improving overweight/obesity with phlegm-dampness according to claim 6, wherein the method comprises the following steps:
the water content of each food/decoction piece after drying is controlled below 8%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311211969.9A CN117159666A (en) | 2023-09-19 | 2023-09-19 | Medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness mass and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311211969.9A CN117159666A (en) | 2023-09-19 | 2023-09-19 | Medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness mass and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117159666A true CN117159666A (en) | 2023-12-05 |
Family
ID=88942888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311211969.9A Pending CN117159666A (en) | 2023-09-19 | 2023-09-19 | Medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness mass and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117159666A (en) |
-
2023
- 2023-09-19 CN CN202311211969.9A patent/CN117159666A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 凡医心苑: "招募，招募，免费招募减肥人员", pages 1 - 5, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s/v19AaiJtE9n-XOfi4_wRjg> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN106617080A (en) | Application of lentinan in preparation of healthcare food with intestinal flora regulating function | |
| CN102526478A (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN111195314A (en) | Traditional Chinese medicine composition for nourishing stomach and promoting digestion and preparation method thereof | |
| CN106617079A (en) | Purpose of ganoderan in preparation of health food for regulating flora in intestinal tract | |
| CN101897925B (en) | Medicinal composition for treating metabolic syndrome | |
| CN111513155B (en) | Composition for preventing and treating lipid metabolism disorder | |
| CN102370738A (en) | Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof | |
| CN117159666A (en) | Medicinal and edible meal replacement composition for improving overweight/obesity with phlegm-dampness mass and preparation method thereof | |
| CN104189294B (en) | A kind of compound Chinese medicinal preparation for treating non-alcoholic fatty liver disease and preparation method thereof | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN110621327A (en) | Composition containing amomum villosum extract for preventing and treating fatty liver | |
| CN102106993B (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN101229265A (en) | Antidiabetics and antiatheroscloresis medicine compounds and preparing method thereof | |
| WO2020244501A1 (en) | Traditional chinese medicine increase and decrease prescription for preventing/treating metabolic syndrome and complications thereof | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN102552702A (en) | Application of Dendrobium officinale in preparing medicaments for treating low gastric acidity type chronic atrophic gastritis | |
| KR20040062832A (en) | Pharmaceutical composition for medical treatments and prevention of obesity including herbal medicine extracts | |
| CN105998049A (en) | Application of dendrobium polysaccharides in preparation of medicines and health products for preventing and treating metabolic syndrome | |
| CN110064016A (en) | A kind of Chinese medicine composition and preparation method thereof adjusting chronic kidney disease immune state | |
| CN101181349B (en) | Application of Salvia przewalskii Maxim extract in the preparation of medicament for curing nephritis of renal glomerulus | |
| WO2014086255A1 (en) | Use of composition of yam polysaccharides and yam proteins | |
| CN115487260B (en) | Traditional Chinese medicine composition for treating hypercholesterolemia or atherosclerosis and application thereof | |
| Park et al. | Dangnyohwan improves glucose utilization and reduces insulin resistance by increasing the adipocyte-specific GLUT4 expression in Otsuka Long-Evans Tokushima Fatty rats | |
| CN106822252A (en) | A kind of Chinese medicine composition with promotion white adipocyte brown and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |